| 2026-09-11 16:51 |
DEFM14A |
|
merger agreement |
0.98
|
Definitive DEFM14A merger agreement between Indivior and Supernus; all-stock merger of equals with fixed 1.5401 exchange ratio. |
SEC · detail |
| 2026-08-03 17:00 |
8-K |
["8.01"] |
merger agreement |
0.98
|
Supernus announces proposed merger of equals with Indivior Pharmaceuticals; 8-K filing includes proxy solicitation rules (Rules 425 & 14a-12). |
SEC · detail |
| 2026-08-03 08:34 |
8-K |
["8.01"] |
merger agreement |
0.98
|
Supernus and Indivior announce proposed merger; joint proxy statement/prospectus and S-4 registration filing imminent. |
SEC · detail |
| 2026-08-03 06:46 |
8-K |
["2.02"] |
merger agreement |
0.98
|
Definitive all-stock merger agreement between Supernus and Indivior Pharmaceuticals announced; merger of equals with joint proxy filing. |
SEC · detail |
| 2026-08-03 06:43 |
8-K |
["1.01"] |
merger agreement |
0.98
|
Supernus entered definitive Merger Agreement with Indivior on Aug 1, 2026; merger of equals with fixed 1.5401 exchange ratio. |
SEC · detail |
| 2026-07-22 17:07 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine earnings announcement; no M&A-related content detected. |
SEC · detail |
| 2026-06-18 16:55 |
8-K |
["5.07", "9.01"] |
other |
0.05
|
Routine annual stockholder meeting with director elections and equity plan amendment; no M&A signals present. |
SEC · detail |
| 2026-05-20 16:37 |
8-K |
["2.03", "9.01"] |
other |
0.05
|
CVR milestone payment obligation triggered; routine post-acquisition earnout distribution, not M&A signal. |
SEC · detail |
| 2026-05-05 16:09 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine Q1 2026 earnings announcement with conference call; no M&A signals. |
SEC · detail |